Celgene (BUE:CELG) Marketable Securities: ARS72,312.32 Mil (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Celgene Marketable Securities?

Celgene BUE:CELG 10 Marketable Securities is ARS72,312.32 Mil as of Sep. 2019. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Celgene's Marketable Securities for the quarter that ended in Sep. 2019 was ARS72,312.32 Mil.

Celgene's annual Marketable Securities increased from Dec. 2016 (ARS28,534.50 Mil) to Dec. 2017 (ARS96,028.75 Mil) but then declined from Dec. 2017 (ARS96,028.75 Mil) to Dec. 2018 (ARS68,170.64 Mil).

Celgene  (BUE:CELG) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Celgene Marketable Securities Related Terms

Celgene Marketable Securities Historical Data

* Premium members only.

The historical data trend for Celgene's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celgene Marketable Securities Chart

Celgene Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29,288.03 21,635.52 28,534.50 96,028.75 68,170.64

Celgene Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69,844.50 68,170.64 88,265.22 94,228.01 72,312.32

Celgene Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ARS72,312.32 Mil mean?
Celgene (BUE:CELG) has a Marketable Securities of ARS72,312.32 Mil as of Sep. 2019. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Celgene and its competitors.
Is Celgene's Marketable Securities too high?
Celgene's current Marketable Securities is ARS72,312.32 Mil. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's Marketable Securities compare to GILD and BIIB?
Celgene's Marketable Securities of ARS72,312.32 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Celgene and its competitors. Celgene's current Marketable Securities is ARS72,312.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current Marketable Securities of ARS72,312.32 Mil. The current Marketable Securities is ARS72,312.32 Mil. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Celgene (BUE:CELG), the current Marketable Securities is ARS72,312.32 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celgene Business Description

Address 86 Morris Avenue, Summit, NJ, USA, 07901
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.